Almac has the most unique and extensive range of integrated drug development services available to the pharmaceutical & biotech industry. Employing over 2,600 individuals, the privately owned organisation is headquartered in Northern Ireland and has extensive facilities in the UK and US. Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical or Clinical Development needs. Our world class pharmaceutical solutions extend from research, through clinical development to the commercialisation of product. Almac has added to its current rapidd™ package (First in Man) to include biomarker development. rapidd™ offers a complete set of solutions aimed at accelerating entry into early stage clinical development. This is a lean, efficient, integrated solution from selection of pre-clinical candidate to Phase I regulatory submission saving up to 12 months and improving attrition of early clinical candidate.. Rapidd™ includes: - Process and analytical development - cGMP manufacture for small molecule or peptides - Radio-labelling / Stable-labelling - Solid-State Services / Polymorph Screening - Pre-Formulation / Formulation Development - Pre-clinical safety assessment - Pharmacodynamic Biomarker - Regulatory support (CTA/IND submission) All of the above services are available individually and include one of the world’s most extensive biocatalysis technology platforms. Benefits from using biocatalysis methods include reduced energy costs, lowered impact on the environment, improved yield and timelines in production of complex chiral APIs and intermediates. Almac offers a fully integrated product manufacturing service, including API and Drug Product from Clinical to Commercial supply.